AU2002360376B2 - Modulation of LIR function to treat rheumatoid arthritis - Google Patents

Modulation of LIR function to treat rheumatoid arthritis Download PDF

Info

Publication number
AU2002360376B2
AU2002360376B2 AU2002360376A AU2002360376A AU2002360376B2 AU 2002360376 B2 AU2002360376 B2 AU 2002360376B2 AU 2002360376 A AU2002360376 A AU 2002360376A AU 2002360376 A AU2002360376 A AU 2002360376A AU 2002360376 B2 AU2002360376 B2 AU 2002360376B2
Authority
AU
Australia
Prior art keywords
pro
ser
leu
gin
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002360376A
Other languages
English (en)
Other versions
AU2002360376A1 (en
Inventor
Jonathan P. Arm
Luis G. Borges
Nicodemus Tedla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Immunex Corp
Original Assignee
Brigham and Womens Hospital Inc
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, Immunex Corp filed Critical Brigham and Womens Hospital Inc
Publication of AU2002360376A1 publication Critical patent/AU2002360376A1/en
Assigned to IMMUNEX CORPORATION reassignment IMMUNEX CORPORATION Amend patent request/document other than specification (104) Assignors: Immunex Corporation, Arm, Jonathon, P., Tedla, Nicodemus and Borges, Luis, G.
Assigned to THE BRIGHAM AND WOMEN'S HOSPITAL, INC, IMMUNEX CORPORATION reassignment THE BRIGHAM AND WOMEN'S HOSPITAL, INC Amend patent request/document other than specification (104) Assignors: Refer to Publication History
Application granted granted Critical
Publication of AU2002360376B2 publication Critical patent/AU2002360376B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2002360376A 2001-11-14 2002-11-12 Modulation of LIR function to treat rheumatoid arthritis Ceased AU2002360376B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33589901P 2001-11-14 2001-11-14
US60/335,899 2001-11-14
PCT/US2002/036372 WO2003041650A2 (en) 2001-11-14 2002-11-12 Modulation of lir function to treat rheumatoid arthritis

Publications (2)

Publication Number Publication Date
AU2002360376A1 AU2002360376A1 (en) 2003-07-24
AU2002360376B2 true AU2002360376B2 (en) 2006-05-18

Family

ID=30770813

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002360376A Ceased AU2002360376B2 (en) 2001-11-14 2002-11-12 Modulation of LIR function to treat rheumatoid arthritis

Country Status (8)

Country Link
US (1) US20050238643A1 (OSRAM)
EP (1) EP1453540A4 (OSRAM)
JP (1) JP2005532256A (OSRAM)
AU (1) AU2002360376B2 (OSRAM)
CA (1) CA2466118A1 (OSRAM)
MX (1) MXPA04004491A (OSRAM)
PL (1) PL374463A1 (OSRAM)
WO (1) WO2003041650A2 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006049215A1 (ja) * 2004-11-02 2006-05-11 Dainippon Sumitomo Pharma Co., Ltd. 自己免疫疾患を治療するための併用薬
GB0510627D0 (en) 2005-05-25 2005-06-29 Avidex Ltd Polypeptides
US8901281B2 (en) 2005-06-17 2014-12-02 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
AU2007345745C1 (en) 2006-06-19 2013-05-23 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
PE20091969A1 (es) * 2008-05-13 2010-01-15 Genentech Inc ANTICUERPOS ANTI-PirB
WO2010101192A1 (ja) * 2009-03-03 2010-09-10 国立大学法人九州大学 関節リウマチまたはその関連疾患の予防または治療剤
WO2011091177A1 (en) * 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
EP2525822B1 (en) * 2010-01-20 2017-05-10 Merck Sharp & Dohme Corp. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
CA2888647A1 (en) * 2012-11-20 2014-05-30 Revive Therapeutics Inc. The use of bucillamine in the treatment of gout
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
CA3087166A1 (en) 2017-12-22 2019-06-27 Jounce Therapeutics, Inc. Antibodies to lilrb2
TWI819024B (zh) 2018-07-09 2023-10-21 美商戊瑞治療有限公司 結合至ｉｌｔ４的抗體
EP4103613A1 (en) * 2020-02-12 2022-12-21 BioInvent International AB Lilrb3 antibody molecules and uses thereof
AU2021265801B2 (en) 2020-05-01 2026-04-02 Ngm Biopharmaceuticals, Inc. ILT-binding agents and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055335A2 (en) * 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031806A2 (en) * 1997-01-21 1998-07-23 Human Genome Sciences, Inc. Fc RECEPTORS AND POLYPEPTIDES
US6384203B1 (en) * 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6448035B1 (en) * 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055335A2 (en) * 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lepin et al. (see ISR) *

Also Published As

Publication number Publication date
WO2003041650A3 (en) 2004-01-29
PL374463A1 (en) 2005-10-17
CA2466118A1 (en) 2003-05-22
MXPA04004491A (es) 2005-05-16
WO2003041650A2 (en) 2003-05-22
JP2005532256A (ja) 2005-10-27
EP1453540A4 (en) 2005-06-01
EP1453540A2 (en) 2004-09-08
US20050238643A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
RU2722451C1 (ru) Pd-1 антитела и их применение.
AU705114B2 (en) Fas antagonists and uses thereof
AU781998B2 (en) Receptor on the surface of activated T-cells: ACTS-4
US20200095305A1 (en) Methods of modulating immune responses using bcma polypeptide
JP3703834B2 (ja) 活性化ｃｄ４▲上＋▼ｔ細胞の表層上のレセプターに対するリガンド（ａｃｔ−４−ｌ）
AU764257B2 (en) Methods of using human receptor protein 4-1BB
SK141999A3 (en) Osteoprotegerin binding proteins and receptors
US7071310B1 (en) Antibody against the human toll- like receptor 2 (tlr2) and uses thereof
CZ297633B6 (cs) Pouzití BCMA pro výrobu farmaceutického prípravkupro lécení nádoru exprimujících APRIL
US20050238643A1 (en) Modulation of lir function to treat rheumatoid arthritis
JP2007529204A (ja) Ｔｉｍ−１、ｔｉｍ−２、およびｔｉｍ−４の機能を調節することによって免疫応答を調節する方法
AU2002360376A1 (en) Modulation of LIR function to treat rheumatoid arthritis
US6015559A (en) Fas antagonists
US20030021785A1 (en) Use of rank antagonists to treat cancer
WO1999026977A1 (en) Novel receptors opg-2
EP1708961A2 (en) Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
WO2000027873A9 (en) Interleukin-2 binding protein from arthropods

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT FROM IMMUNEX CORPORATION, ARM, JONATHON, P., TEDLA, NICODEMUS AND BORGES, LUIS, G. TO IMMUNEX CORPORATION.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD CO-APPLICANT THE BRIGHAM AND WOMEN S HOSPITAL, INC

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired